Oxidative stress and myocarditis

Current Pharmaceutical Design

Volumn 22, Issue 4, 2016, Pages 450-471

  Tada, Yuko ^a   Suzuki, Jun Ichi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Acute myocarditis; Chronic myocarditis; Oxidative stress

Indexed keywords

ALLOPURINOL; ANGIOGENESIS MODULATOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIOXIDANT; APOCYNIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FREE RADICAL; HYDROGEN PEROXIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; KELCH LIKE ECH ASSOCIATED PROTEIN 1; NITRIC OXIDE; PHOSPHATASE; PHOSPHOLIPASE; POLYPHENOL; PROSTAGLANDIN SYNTHASE; PROTEASOME; PROTEIN KINASE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SUPEROXIDE; TRANSCRIPTION FACTOR NRF2; UBIDECARENONE; UBIQUITIN; VASODILATOR AGENT; XANTHINE OXIDASE; AUTACOID;

ADAPTIVE IMMUNITY; ANTIINFLAMMATORY ACTIVITY; ANTIVIRAL ACTIVITY; APOPTOSIS; AUTOIMMUNITY; BLOOD VESSEL FUNCTION; CALCIUM SIGNALING; CARDIOMYOPATHY; CELL DEATH; CELL DIFFERENTIATION; CELL SURVIVAL; DISEASE COURSE; DRUG EFFECT; ENZYME ACTIVATION; FIBROSING ALVEOLITIS; GENE EXPRESSION; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPOXEMIA; INFLAMMATION; INNATE IMMUNITY; KALLIKREIN KININ SYSTEM; MITOCHONDRIAL RESPIRATION; MYOCARDITIS; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PERSISTENT INFECTION; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RESPIRATORY CHAIN; REVIEW; SIGNAL TRANSDUCTION; TISSUE INJURY; ANIMAL; IMMUNOLOGY; METABOLISM; PHYSIOLOGY;

ANIMALS; FREE RADICALS; HUMANS; INFLAMMATION MEDIATORS; MYOCARDITIS; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES;

EID: 84959334308     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612822666151222160559     Document Type: Review

References (291)

1. Cooper LT. Myocarditis. N Engl J Med 2009; 360: 1526-38.
2. Felker GM, Thompson RE, Hare JM, et al. Underlying causes andlong-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 2000; 342: 1077-84.
3. Cohen G. Enzymatic/nonenzymatic sources of oxyradicals andregulation of antioxidant defenses. Ann N Y Acad Sci 1994; 738: 8-14.
4. Bedard K, Krause KH. The NOX family of ROS-generatingNADPH oxidases: physiology and pathophysiology. Physiol Rev 2007; 87: 245-313.
5. Roos G, Messens J. Protein sulfenic acid formation: from cellulardamage to redox regulation. Free Radic Biol Med 2011; 51: 314-26.
6. Kamata H, Honda S, Maeda S, Chang L, Hirata H, Karin M. Reactive oxygen species promote TNFalpha-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases. Cell 2005; 120: 649-61.
7. Irani K. Oxidant signaling in vascular cell growth, death, andsurvival: a review of the roles of reactive oxygen species in smooth muscle and endothelial cell mitogenic and apoptotic signaling. Circ Res 2000; 87: 179-83.
8. Giannoni E, Taddei ML, Chiarugi P. Src redox regulation: again inthe front line. Free Radic Biol Med 2010; 49: 516-27.
9. Yoo SK, Starnes TW, Deng Q, Huttenlocher A. Lyn is a redoxsensor that mediates leukocyte wound attraction in vivo. Nature 2011; 480: 109-12.
10. Burgoyne JR, Madhani M, Cuello F, et al. Cysteine redox sensor inPKGIa enables oxidant-induced activation. Science 2007; 317: 1393-7.
11. Sun G, Kemble DJ. To C or not to C: direct and indirect redoxregulation of Src protein tyrosine kinase. Cell Cycle 2009; 8: 2353-5.
12. van der Vliet A, Janssen-Heininger YM. Hydrogen peroxide as adamage signal in tissue injury and inflammation: murderer, mediator, or messenger? J Cell Biochem 2014; 115: 427-35.
13. van der Vliet A. NADPH oxidases in lung biology and pathology:host defense enzymes, and more. Free Radic Biol Med 2008; 44: 938-55.
14. Liu G, Pessah IN. Molecular interaction between ryanodinereceptor and glycoprotein triadin involves redox cycling of functionally important hyperreactive sulfhydryls. J Biol Chem 1994; 269: 33028-34.
15. Cheranov SY, Jaggar JH. TNF-alpha dilates cerebral arteries viaNAD(P)H oxidase-dependent Ca2+ spark activation. Am J Physiol Cell Physiol 2006; 290: C964-71.
16. Ha H, Lee HB. Reactive oxygen species amplify glucose signallingin renal cells cultured under high glucose and in diabetic kidney. Nephrology (Carlton) 2005; 10 Suppl: S7-S10.
17. Qin L, Liu Y, Qian X, Hong JS, Block ML. Microglial NADPHoxidase mediates leucine enkephalin dopaminergic neuroprotection. Ann N Y Acad Sci 2005; 1053: 107-20.
18. Sun Y, Oberley LW. Redox regulation of transcriptional activators.Free Radic Biol Med 1996; 21: 335-48.
19. Piacenza L, Peluffo G, Alvarez MN, Kelly JM, Wilkinson SR, Radi R. Peroxiredoxins play a major role in protecting Trypanosoma cruzi against macrophage-and endogenously-derived peroxynitrite. Biochem J 2008; 410: 359-68.
20. Kang SM, Lim S, Song H, et al. Allopurinol modulates reactiveoxygen species generation and Ca2+ overload in ischemia-reperfused heart and hypoxia-reoxygenated cardiomyocytes. Eur J Pharmacol 2006; 535: 212-9.
21. Elsayed NM, Nakashima JM, Postlethwait EM. Measurement ofuric acid as a marker of oxygen tension in the lung. Arch Biochem Biophys 1993; 302: 228-32.
22. Wiedemann HR., L. Emmet Holt Jr.. (1895-1974). Eur J Pediatr1993; 152: 973.
23. Tamariz L, Harzand A, Palacio A, Verma S, Jones J, Hare J. Uricacid as a predictor of all-cause mortality in heart failure: a metaanalysis. Congest Heart Fail 2011; 17: 25-30.
24. Kanbay A, Inonu H, Solak Y, et al. Uric acid as a potentialmediator of cardiovascular morbidity in obstructive sleep apnea syndrome. Eur J Intern Med 2014; 25: 471-6.
25. Kim JW, Baek BS, Kim YK, et al. Gene expression ofcyclooxygenase in the aging heart. J Gerontol A Biol Sci Med Sci 2001; 56: B350-355.
26. Mengle-Gaw LJ, Schwartz BD. Cyclooxygenase-2 inhibitors:promise or peril? Mediat Inflamm 2002; 11: 275-86.
27. Park HS, Jung HY, Park EY, Kim J, Lee WJ, Bae YS. Cuttingedge: direct interaction of TLR4 with NAD(P)H oxidase 4 isozyme is essential for lipopolysaccharide-induced production of reactive oxygen species and activation of NF-kappa B. J Immunol 2004; 173: 3589-93.
28. Gorin Y, Ricono JM, Kim NH, Bhandari B, Choudhury GG, Abboud HE. Nox4 mediates angiotensin II-induced activation of Akt/protein kinase B in mesangial cells. Am J Physiol Renal Physiol 2003; 285: F219-F229.
29. Martyn KD, Frederick LM, von Loehneysen K, Dinauer MC, Knaus UG. Functional analysis of Nox4 reveals unique characteristics compared to other NADPH oxidases. Cell Signal 2006; 18: 69-82.
30. Maejima Y, Kuroda J, Matsushima S, Ago T, Sadoshima J. Regulation of myocardial growth and death by NADPH oxidase. J Mol Cell Cardiol 2011; 50: 408-16.
31. Akki A, Zhang M, Murdoch C, Brewer A, Shah AM. NADPHoxidase signaling and cardiac myocyte function. J Mol Cell Cardiol 2009; 47: 15-22.
32. Bogdan C. Nitric oxide and the immune response. Nat Immunol2001; 2: 907-16.
33. Li Y, Huang TT, Carlson EJ, et al. Dilated cardiomyopathy andneonatal lethality in mutant mice lacking manganese superoxide dismutase. Nat Genet 1995; 11: 376-81.
34. Rhee SG, Kang SW, Chang TS, Jeong W, Kim K. Peroxiredoxin, anovel family of peroxidases. IUBMB Life 2001; 52: 35-41.
35. Ago T, Sadoshima J. Thioredoxin and ventricular remodeling. JMol Cell Cardiol 2006; 41: 762-73.
36. Zenkov NK, Menshchikova EB, Tkachev VO. Keap1/Nrf2/AREredox-sensitive signaling system as a pharmacological target. Biochemistry (Mosc) 2013; 78: 19-36.
37. Faraonio R, Vergara P, Di Marzo D, et al. p53 suppresses the Nrf2-dependent transcription of antioxidant response genes. J Biol Chem 2006; 281: 39776-84.
38. Yu M, Li H, Liu Q, et al. Nuclear factor p65 interacts with Keap1to repress the Nrf2-ARE pathway. Cell Signal 2011; 23: 883-92.
39. Liu GH, Qu J, Shen X. NF-kappaB/p65 antagonizes Nrf2-AREpathway by depriving CBP from Nrf2 and facilitating recruitment of HDAC3 to MafK. Biochim Biophys Acta 2008; 1783: 713-27.
40. Khor TO, Huang MT, Kwon KH, Chan JY, Reddy BS, Kong AN. Nrf2-deficient mice have an increased susceptibility to dextran sulfate sodium-induced colitis. Cancer Res 2006; 66: 11580-4.
41. Yokoseki O, Suzuki J, Kitabayashi H, et al. cis Element decoyagainst nuclear factor-kappaB attenuates development of experimental autoimmune myocarditis in rats. Circ Res 2001; 89: 899-906.
42. Watanabe R, Azuma RW, Suzuki J, et al. Inhibition of NF-Bactivation by a novel IKK inhibitor reduces the severity of experimental autoimmune myocarditis via suppression of T-cell activation. Am J Physiol Heart Circ Physiol 2013; 305: H1761-H1771.
43. Bagnoli M, Canevari S, Mezzanzanica D. Cellular FLICE-inhibitory protein (c-FLIP) signalling: a key regulator of receptor-mediated apoptosis in physiologic context and in cancer. Int J Biochem Cell Biol 2010; 42: 210-3.
44. Jones PL, Ping D, Boss JM. Tumor necrosis factor alpha andinterleukin-1beta regulate the murine manganese superoxide dismutase gene through a complex intronic enhancer involving C/EBP-beta and NF-kappaB. Mol Cell Biol 1997; 17: 6970-81.
45. Djavaheri-Mergny M, Javelaud D, Wietzerbin J, Besançon F. NF-kappaB activation prevents apoptotic oxidative stress via an increase of both thioredoxin and MnSOD levels in TNFalpha-treated Ewing sarcoma cells. FEBS Lett 2004; 578: 111-5.
46. Rojo AI, Salinas M, Martín D, Perona R, Cuadrado A. Regulationof Cu/Zn-superoxide dismutase expression via the phosphatidylinositol 3 kinase/Akt pathway and nuclear factor-kappaB. J Neurosci 2004; 24: 7324-34.
47. Pham CG, Bubici C, Zazzeroni F, et al. Ferritin heavy chainupregulation by NF-kappaB inhibits TNFalpha-induced apoptosis by suppressing reactive oxygen species. Cell 2004; 119: 529-42.
48. Kairisalo M, Korhonen L, Blomgren K, Lindholm D. X-linkedinhibitor of apoptosis protein increases mitochondrial antioxidants through NF-kappaB activation. Biochem Biophys Res Commun 2007; 364: 138-44.
49. Lavrovsky Y, Schwartzman ML, Levere RD, Kappas A, Abraham NG. Identification of binding sites for transcription factors NF-kappa B and AP-2 in the promoter region of the human heme oxygenase 1 gene. Proc Natl Acad Sci USA 1994; 91: 5987-91.
50. Lin CC, Chiang LL, Lin CH, et al. Transforming growth factor-beta1 stimulates heme oxygenase-1 expression via the PI3K/Akt and NF-kappaB pathways in human lung epithelial cells. Eur J Pharmacol 2007; 560: 101-9.
51. Anrather J, Racchumi G, Iadecola C. NF-kappaB regulatesphagocytic NADPH oxidase by inducing the expression of gp91phox. J Biol Chem 2006; 281: 5657-67.
52. Morris KR, Lutz RD, Choi HS, Kamitani T, Chmura K, Chan ED. Role of the NF-kappaB signaling pathway and kappaB cisregulatory elements on the IRF-1 and iNOS promoter regions in mycobacterial lipoarabinomannan induction of nitric oxide. Infect Immun 2003; 71: 1442-52.
53. Kolyada AY, Savikovsky N, Madias NE. Transcriptional regulationof the human iNOS gene in vascular-smooth-muscle cells and macrophages: evidence for tissue specificity. Biochem Biophys Res Commun 1996; 220: 600-5.
54. Guo Z, Shao L, Du Q, Park KS, Geller DA. Identification of aclassic cytokine-induced enhancer upstream in the human iNOS promoter. FASEB J 2007; 21: 535-42.
55. Deng WG, Zhu Y, Wu KK. Up-regulation of p300 binding and p50acetylation in tumor necrosis factor-alpha-induced cyclooxygenase-2 promoter activation. J Biol Chem 2003; 278: 4770-7.
56. Toledano MB, Leonard WJ. Modulation of transcription factor NF-kappa B binding activity by oxidation-reduction in vitro. Proc Natl Acad Sci USA 1991; 88: 4328-32.
57. Matthews JR, Kaszubska W, Turcatti G, Wells TN, Hay RT. Roleof cysteine62 in DNA recognition by the P50 subunit of NF-kappaB. Nucleic Acids Res 1993; 21: 1727-34.
58. Reynaert NL, van der Vliet A, Guala AS, et al. Dynamic redoxcontrol of NF-kappaB through glutaredoxin-regulated S-glutathionylation of inhibitory kappaB kinase beta. Proc Natl Acad Sci USA 2006; 103: 13086-91.
59. Reynaert NL, Ckless K, Korn SH, et al. Nitric oxide repressesinhibitory kappaB kinase through S-nitrosylation. Proc Natl Acad Sci USA 2004; 101: 8945-50.
60. Rossi A, Kapahi P, Natoli G, et al. Anti-inflammatorycyclopentenone prostaglandins are direct inhibitors of IkappaB kinase. Nature 2000; 403: 103-8.
61. Herscovitch M, Comb W, Ennis T, et al. Intermolecular disulfidebond formation in the NEMO dimer requires Cys54 and Cys347. Biochem Biophys Res Commun 2008; 367: 103-8.
62. Kil IS, Kim SY, Park JW. Glutathionylation regulates IkappaB.Biochem Biophys Res Commun 2008; 373: 169-73.
63. Wu M, Bian Q, Liu Y, et al. Sustained oxidative stress inhibits NF-kappaB activation partially via inactivating the proteasome. Free Radic Biol Med 2009; 46: 62-9.
64. Ghigo A, Franco I, Morello F, Hirsch E. Myocyte signalling inleucocyte recruitment to the heart. Cardiovasc Res 2014; 102: 270-80.
65. Badorff C, Lee GH, Lamphear BJ, et al. Enteroviral protease 2Acleaves dystrophin: evidence of cytoskeletal disruption in an acquired cardiomyopathy. Nat Med 1999; 5: 320-6.
66. Ba X, Gupta S, Davidson M, Garg NJ. Trypanosoma cruzi inducesthe reactive oxygen species-PARP-1-RelA pathway for up-regulation of cytokine expression in cardiomyocytes. J Biol Chem 2010; 285: 11596-606.
67. Machado FS, Dutra WO, Esper L, et al. Current understanding ofimmunity to Trypanosoma cruzi infection and pathogenesis of Chagas disease. Semin Immunopathol 2012; 34: 753-70.
68. Klebanoff SJ. Myeloperoxidase: friend and foe. J Leukoc Biol 2005; 77: 598-625.
69. Lassègue B, San Martín A, Griendling KK. Biochemistry,physiology, and pathophysiology of NADPH oxidases in the cardiovascular system. Circ Res 2012; 110: 1364-90.
70. Savina A, Jancic C, Hugues S, et al. NOX2 controls phagosomalpH to regulate antigen processing during crosspresentation by dendritic cells. Cell 2006; 126: 205-18.
71. Reeves EP, Lu H, Jacobs HL, et al. Killing activity of neutrophilsis mediated through activation of proteases by K+ flux. Nature 2002; 416: 291-7.
72. Ryan KA, Smith MF, Sanders MK, Ernst PB. Reactive oxygen andnitrogen species differentially regulate Toll-like receptor 4-mediated activation of NF-kappa B and interleukin-8 expression. Infect Immun 2004; 72: 2123-30.
73. Matsuzawa A, Saegusa K, Noguchi T, et al. ROS-dependentactivation of the TRAF6-ASK1-p38 pathway is selectively required for TLR4-mediated innate immunity. Nat Immunol 2005; 6: 587-92.
74. Liu Y, Shepherd EG, Nelin LD. MAPK phosphatases--regulatingthe immune response. Nat Rev Immunol 2007; 7: 202-12.
75. Allam R, Darisipudi MN, Tschopp J, Anders HJ. Histones triggersterile inflammation by activating the NLRP3 inflammasome. Eur J Immunol 2013; 43: 3336-42.
76. Wang Y, Gao B, Xiong S. Involvement of NLRP3 inflammasomein CVB3-induced viral myocarditis. Am J Physiol Heart Circ Physiol 2014; 307: H1438-47.
77. Segal BH, Grimm MJ, Khan AN, Han W, Blackwell TS. Regulation of innate immunity by NADPH oxidase. Free Radic Biol Med 2012; 53: 72-80.
78. Matsue H, Edelbaum D, Shalhevet D, et al. Generation andfunction of reactive oxygen species in dendritic cells during antigen presentation. J Immunol 2003; 171: 3010-8.
79. Maly FE, Cross AR, Jones OT, et al. The superoxide generatingsystem of B cell lines. Structural homology with the phagocytic oxidase and triggering via surface Ig. J Immunol 1988; 140: 2334-9.
80. Reth M. Hydrogen peroxide as second messenger in lymphocyteactivation. Nat Immunol 2002; 3: 1129-34.
81. Capasso M, DeCoursey TE, Dyer MJ. pH regulation and beyond:unanticipated functions for the voltage-gated proton channel, HVCN1. Trends Cell Biol 2011; 21: 20-8.
82. Masciarelli S, Sitia R. Building and operating an antibody factory:redox control during B to plasma cell terminal differentiation. Biochim Biophys Acta 2008; 1783: 578-88.
83. Dhiman M, Garg NJ. NADPH oxidase inhibition amelioratesTrypanosoma cruzi-induced myocarditis during Chagas disease. J Pathol 2011; 225: 583-96.
84. Stroupe KT, Morrison DA, Hlatky MA, et al. Cost-effectiveness ofcoronary artery bypass grafts versus percutaneous coronary intervention for revascularization of high-risk patients. Circulation 2006; 114: 1251-7.
85. Ino T, Kishiro M, Okubo M, et al. Late persistent expressions ofICAM-1 and VCAM-1 on myocardial tissue in children with lymphocytic myocarditis. Cardiovasc Res 1997; 34: 323-8.
86. Zhang AY, Yi F, Zhang G, Gulbins E, Li PL. Lipid raft clusteringand redox signaling platform formation in coronary arterial endothelial cells. Hypertension 2006; 47: 74-80.
87. Simpson CS, Morris BJ. Regulation of neuronal cell adhesionmolecule expression by NF-kappa B. J Biol Chem 2000; 275: 16879-84.
88. Arbiser JL, Petros J, Klafter R, et al. Reactive oxygen generated byNox1 triggers the angiogenic switch. Proc Natl Acad Sci USA 2002; 99: 715-20.
89. Chen XL, Zhang Q, Zhao R, Medford RM. Superoxide, H2O2, andiron are required for TNF-alpha-induced MCP-1 gene expression in endothelial cells: role of Rac1 and NADPH oxidase. Am J Physiol Heart Circ Physiol 2004; 286: H1001-7.
90. Zhang L, Zalewski A, Liu Y, et al. Diabetes-induced oxidativestress and low-grade inflammation in porcine coronary arteries. Circulation 2003; 108: 472-8.
91. Schröder K, Zhang M, Benkhoff S, et al. Nox4 is a protectivereactive oxygen species generating vascular NADPH oxidase. Circ Res 2012; 110: 1217-25.
92. Park HS, Chun JN, Jung HY, Choi C, Bae YS. Role of NADPHoxidase 4 in lipopolysaccharide-induced proinflammatory responses by human aortic endothelial cells. Cardiovasc Res 2006; 72: 447-55.
93. Anilkumar N, San Jose G, Sawyer I, et al. A 28-kDa splice variantof NADPH oxidase-4 is nuclear-localized and involved in redox signaling in vascular cells. Arterioscler Thromb Vasc Biol 2013; 33: e104-e112.
94. Eckert JW, Abramson SL, Starke J, Brandt ML. The surgicalimplications of chronic granulomatous disease. Am J Surg 1995; 169: 320-3.
95. Sen CK. The general case for redox control of wound repair.Wound Repair Regen 2003; 11: 431-8.
96. Pase L, Layton JE, Wittmann C, et al. Neutrophil-deliveredmyeloperoxidase dampens the hydrogen peroxide burst after tissue wounding in zebrafish. Curr Biol 2012; 22: 1818-24.
97. Niethammer P, Grabher C, Look AT, Mitchison TJ. A tissue-scalegradient of hydrogen peroxide mediates rapid wound detection in zebrafish. Nature 2009; 459: 996-9.
98. West XZ, Malinin NL, Merkulova AA, et al. Oxidative stressinduces angiogenesis by activating TLR2 with novel endogenous ligands. Nature 2010; 467: 972-6.
99. Allam R, Kumar SV, Darisipudi MN, Anders HJ. Extracellularhistones in tissue injury and inflammation. J Mol Med (Berl) 2014; 92: 465-72.
100. Ito K, Hirao A, Arai F, et al. Reactive oxygen species act throughp38 MAPK to limit the lifespan of hematopoietic stem cells. Nat Med 2006; 12: 446-51.
101. Mochizuki T, Furuta S, Mitsushita J, et al. Inhibition of NADPHoxidase 4 activates apoptosis via the AKT/apoptosis signal- regulating kinase 1 pathway in pancreatic cancer PANC-1 cells. Oncogene 2006; 25: 3699-707.
102. Owusu-Ansah E, Banerjee U. Reactive oxygen species primeDrosophila haematopoietic progenitors for differentiation. Nature 2009; 461: 537-41.
103. Li YC, Ge LS, Yang PL, et al. Carvedilol treatment amelioratesacute coxsackievirus B3-induced myocarditis associated with oxidative stress reduction. Eur J Pharmacol 2010; 640: 112-6.
104. Dhiman M, Wan X, Popov VL, Vargas G, Garg NJ. MnSODtgmice control myocardial inflammatory and oxidative stress and remodeling responses elicited in chronic Chagas disease. J Am Heart Assoc 2013; 2: e000302.
105. Chen P, Zhou J. Abnormal metabolism of nitric oxide, oxidativestress and lipoperoxidative stress in patients with acute viral myocarditis. Chin Med J (Engl) 2001; 114: 1132-5.
106. Kodama M, Matsumoto Y, Fujiwara M, Masani F, Izumi T,Shibata A. A novel experimental model of giant cell myocarditis induced in rats by immunization with cardiac myosin fraction. Clin Immunol Immunopathol 1990; 57: 250-62.
107. Neu N, Beisel KW, Traystman MD, Rose NR, Craig SW.Autoantibodies specific for the cardiac myosin isoform are found in mice susceptible to Coxsackievirus B3-induced myocarditis. J Immunol 1987; 138: 2488-92.
108. Rowe GT, Manson NH, Caplan M, Hess ML. Hydrogen peroxideand hydroxyl radical mediation of activated leukocyte depression of cardiac sarcoplasmic reticulum. Participation of the cyclooxygenase pathway. Circ Res 1983; 53: 584-91.
109. Rowe GT, Eaton LR, Hess ML. Neutrophil-derived, oxygen freeradical-mediated cardiovascular dysfunction. J Mol Cell Cardiol 1984; 16: 1075-9.
110. Nimata M, Okabe TA, Hattori M, Yuan Z, Shioji K, Kishimoto C.MCI-186 (edaravone), a novel free radical scavenger, protects against acute autoimmune myocarditis in rats. Am J Physiol Heart Circ Physiol 2005; 289: H2514-8.
111. Yin G, Wang Y, Cen XM, Yang M, Liang Y, Xie QB. Lipidperoxidation-mediated inflammation promotes cell apoptosis through activation of NF- B pathway in rheumatoid arthritis synovial cells. Mediat Inflamm 2015; 2015: 460310.
112. Kumagai T, Kawamoto Y, Nakamura Y, et al. 4-hydroxy-2-nonenal, the end product of lipid peroxidation, is a specific inducer of cyclooxygenase-2 gene expression. Biochem Biophys Res Commun 2000; 273: 437-41.
113. Ebermann L, Wika S, Klumpe I, et al. The mitochondrialrespiratory chain has a critical role in the antiviral process in Coxsackievirus B3-induced myocarditis. Lab Invest 2012; 92: 125-34.
114. Abbate A, Sinagra G, Bussani R, et al. Apoptosis in patients withacute myocarditis. Am J Cardiol 2009; 104: 995-1000.
115. Dörner A, Pauschinger M, Schwimmbeck PL, Kühl U, SchultheissHP. The shift in the myocardial adenine nucleotide translocator isoform expression pattern is associated with an enteroviral infection in the absence of an active T-cell dependent immune response in human inflammatory heart disease. J Am Coll Cardiol 2000; 35: 1778-84.
116. Schulze K, Witzenbichler B, Christmann C, Schultheiss HP.Disturbance of myocardial energy metabolism in experimental virus myocarditis by antibodies against the adenine nucleotide translocator. Cardiovasc Res 1999; 44: 91-100.
117. Xu J, Nie HG, Zhang XD, Tian Y, Yu B. Down-regulated energymetabolism genes associated with mitochondria oxidative phosphorylation and fatty acid metabolism in viral cardiomyopathy mouse heart. Mol Biol Rep 2011; 38: 4007-13.
118. Alter P, Maisch B. Escape from cardiomyocyte apoptosis byenterovirus persistence due to elevated soluble Fas-receptors. Z Kardiol 2004; 93: 524-32.
119. Alter P, Jobmann M, Meyer E, Pankuweit S, Maisch B. Apoptosisin myocarditis and dilated cardiomyopathy: does enterovirus genome persistence protect from apoptosis? An endomyocardial biopsy study. Cardiovasc Pathol 2001; 10: 229-34.
120. Zaragoza C, Ocampo C, Saura M, et al. The role of inducible nitricoxide synthase in the host response to Coxsackievirus myocarditis. Proc Natl Acad Sci USA 1998; 95: 2469-74.
121. Szalay G, Sauter M, Hald J, Weinzierl A, Kandolf R, Klingel K.Sustained nitric oxide synthesis contributes to immunopathology in ongoing myocarditis attributable to interleukin-10 disorders. Am J Pathol 2006; 169: 2085-93.
122. Goren N, Leiros CP, Sterin-Borda L, Borda E. Nitric oxidesynthase in experimental autoimmune myocarditis dysfunction. J Mol Cell Cardiol 1998; 30: 2467-74.
123. Kahl KG, Zielasek J, Uttenthal LO, Rodrigo J, Toyka KV, SchmidtHH. Protective role of the cytokine-inducible isoform of nitric oxide synthase induction and nitrosative stress in experimental autoimmune encephalomyelitis of the DA rat. J Neurosci Res 2003; 73: 198-205.
124. Danilov AI, Jagodic M, Wiklund NP, Olsson T, Brundin L. Effectsof long term NOS inhibition on disease and the immune system in MOG induced EAE. Nitric Oxide 2005; 13: 188-95.
125. Wen JJ, Vyatkina G, Garg N. Oxidative damage during chagasiccardiomyopathy development: role of mitochondrial oxidant release and inefficient antioxidant defense. Free Radic Biol Med 2004; 37: 1821-33.
126. Liu W, Nakamura H, Shioji K, et al. Thioredoxin-1 amelioratesmyosin-induced autoimmune myocarditis by suppressing chemokine expressions and leukocyte chemotaxis in mice. Circulation 2004; 110: 1276-83.
127. Beck MA, Esworthy RS, Ho YS, Chu FF. Glutathione peroxidaseprotects mice from viral-induced myocarditis. FASEB J 1998; 12: 1143-9.
128. Beck MA, Kolbeck PC, Shi Q, Rohr LH, Morris VC, Levander OA. Increased virulence of a human enterovirus (coxsackievirus B3) in selenium-deficient mice. J Infect Dis 1994; 170: 351-7.
129. Beck MA, Kolbeck PC, Rohr LH, Shi Q, Morris VC, Levander OA. Vitamin E deficiency intensifies the myocardial injury of coxsackievirus B3 infection of mice. J Nutr 1994; 124: 345-58.
130. Machado FS, Tanowitz HB, Ribeiro AL. Pathogenesis of chagascardiomyopathy: role of inflammation and oxidative stress. J Am Heart Assoc 2013; 2: e000539.
131. Pérez-Fuentes R, Guégan JF, Barnabé C, et al. Severity of chronicChagas disease is associated with cytokine/antioxidant imbalance in chronically infected individuals. Int J Parasitol 2003; 33: 293-9.
132. Shioji K, Kishimoto C, Nakamura H, et al. Upregulation ofthioredoxin (TRX) expression in giant cell myocarditis in rats. FEBS Lett 2000; 472: 109-13.
133. Saitoh M, Nishitoh H, Fujii M, et al. Mammalian thioredoxin is adirect inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO J 1998; 17: 2596-606.
134. Salomon RG, Jirousek MR, Ghosh S, Sharma RB. Prostaglandinendoperoxides 21. Covalent binding of levuglandin E2 with proteins. Prostaglandins 1987; 34: 643-56.
135. DiFranco E, Subbanagounder G, Kim S, et al. Formation andstability of pyrrole adducts in the reaction of levuglandin E2 with proteins. Chem Res Toxicol 1995; 8: 61-7.
136. Erickson JR, Joiner ML, Guan X, et al. A dynamic pathway forcalcium-independent activation of CaMKII by methionine oxidation. Cell 2008; 133: 462-74.
137. Zhang T, Brown JH. Role of Ca2+/calmodulin-dependent proteinkinase II in cardiac hypertrophy and heart failure. Cardiovasc Res 2004; 63: 476-86.
138. Singh MV, Anderson ME. Is CaMKII a link between inflammationand hypertrophy in heart? J Mol Med (Berl) 2011; 89: 537-43.
139. Nishida K, Otsu K. The role of apoptosis signal-regulating kinase 1in cardiomyocyte apoptosis. Antioxid Redox Signal 2006; 8: 1729-36.
140. Balakumar P, Singh M. Possible role of poly(ADP-ribose)polymerase in pathological and physiological cardiac hypertrophy. Methods Find Exp Clin Pharmacol 2006; 28: 683-9.
141. Pacher P, Szabo C. Role of the peroxynitrite-poly(ADP-ribose)polymerase pathway in human disease. Am J Pathol 2008; 173: 2-13.
142. Wen JJ, Gupta S, Guan Z, et al. Phenyl-alpha-tert-butyl-nitrone andbenzonidazole treatment controlled the mitochondrial oxidative stress and evolution of cardiomyopathy in chronic chagasic Rats. J Am Coll Cardiol 2010; 55: 2499-508.
143. Halestrap AP, Clarke SJ, Javadov SA. Mitochondrial permeabilitytransition pore opening during myocardial reperfusion--a target for cardioprotection. Cardiovasc Res 2004; 61: 372-85.
144. Kuroda J, Ago T, Matsushima S, Zhai P, Schneider MD, Sadoshima J. NADPH oxidase 4 (Nox4) is a major source of oxidative stress in the failing heart. Proc Natl Acad Sci USA 2010; 107: 15565-70.
145. Tanowitz HB, Burns ER, Sinha AK, et al. Enhanced plateletadherence and aggregation in Chagas' disease: a potential pathogenic mechanism for cardiomyopathy. Am J Trop Med Hyg 1990; 43: 274-81.
146. Tanowitz HB, Huang H, Jelicks LA, et al. Role of endothelin 1 inthe pathogenesis of chronic chagasic heart disease. Infect Immun 2005; 73: 2496-503.
147. Salomone OA, Caeiro TF, Madoery RJ, et al. High plasmaimmunoreactive endothelin levels in patients with Chagas' cardiomyopathy. Am J Cardiol 2001; 87: 1217-20; A7.
148. Pollock DM. Endothelin, angiotensin, and oxidative stress inhypertension. Hypertension 2005; 45: 477-80.
149. Crea F, Camici PG, Bairey Merz CN. Coronary microvasculardysfunction: an update. Eur Heart J 2014; 35: 1101-11.
150. Yilmaz A, Mahrholdt H, Athanasiadis A, et al. Coronaryvasospasm as the underlying cause for chest pain in patients with PVB19 myocarditis. Heart 2008; 94: 1456-63.
151. Eltzschig HK, Carmeliet P. Hypoxia and inflammation. N Engl JMed 2011; 364: 656-65.
152. Taylor CT. Interdependent roles for hypoxia inducible factor andnuclear factor-kappaB in hypoxic inflammation. J Physiol 2008; 586: 4055-9.
153. Cummins EP, Berra E, Comerford KM, et al. Prolyl hydroxylase-1negatively regulates IkappaB kinase-beta, giving insight into hypoxia-induced NFkappaB activity. Proc Natl Acad Sci USA 2006; 103: 18154-9.
154. Koong AC, Chen EY, Giaccia AJ. Hypoxia causes the activation ofnuclear factor kappa B through the phosphorylation of I kappa B alpha on tyrosine residues. Cancer Res 1994; 54: 1425-30.
155. Kuhlicke J, Frick JS, Morote-Garcia JC, Rosenberger P, Eltzschig HK Hypoxia inducible factor (HIF)-1 coordinates induction of Toll-like receptors TLR2 and TLR6 during hypoxia. PLoS One 2007; 2: e1364.
156. Winning S, Splettstoesser F, Fandrey J, Frede S. Acute hypoxiainduces HIF-independent monocyte adhesion to endothelial cells through increased intercellular adhesion molecule-1 expression: the role of hypoxic inhibition of prolyl hydroxylase activity for the induction of NF-kappa B. J Immunol 2010; 185: 1786-93.
157. Katavetin P, Miyata T, Inagi R, et al. High glucose blunts vascularendothelial growth factor response to hypoxia via the oxidative stress-regulated hypoxia-inducible factor/hypoxia-responsible element pathway. J Am Soc Nephrol 2006; 17: 1405-13.
158. Rosenberger C, Khamaisi M, Abassi Z, et al. Adaptation tohypoxia in the diabetic rat kidney. Kidney Int 2008; 73: 34-42.
159. Karhausen J, Furuta GT, Tomaszewski JE, Johnson RS, Colgan SP, Haase VH. Epithelial hypoxia-inducible factor-1 is protective in murine experimental colitis. J Clin Invest 2004; 114: 1098-106.
160. Tada Y, Ogawa M, Watanabe R, et al. Neovascularization inducedby hypoxia inducible transcription factor is associated with the improvement of cardiac dysfunction in experimental autoimmune myocarditis. Expert Opin Investig Drugs 2014; 23: 149-62.
161. Leyva F, Anker SD, Godsland IF, et al. Uric acid in chronic heartfailure: a marker of chronic inflammation. Eur Heart J 1998; 19: 1814-22.
162. Gibbings S, Elkins ND, Fitzgerald H, et al. Xanthineoxidoreductase promotes the inflammatory state of mononuclear phagocytes through effects on chemokine expression, peroxisome proliferator-activated receptor-{gamma} sumoylation, and HIF- 1{alpha}. J Biol Chem 2011; 286: 961-75.
163. Jarasch ED, Grund C, Bruder G, Heid HW, Keenan TW, Franke WW. Localization of xanthine oxidase in mammary-gland epithelium and capillary endothelium. Cell 1981; 25: 67-82.
164. Lee CI, Liu X, Zweier JL. Regulation of xanthine oxidase by nitricoxide and peroxynitrite. J Biol Chem 2000; 275: 9369-76.
165. Kim NH, Choi S, Han EJ, et al. The xanthine oxidase-NFAT5pathway regulates macrophage activation and TLR-induced inflammatory arthritis. Eur J Immunol 2014; 44: 2721-36.
166. Okamoto H, Mizuno K, Horio T. Monocyte-derived multinucleatedgiant cells and sarcoidosis. J Dermatol Sci 2003; 31: 119-28.
167. Lee BH, Hwang DM, Palaniyar N, Grinstein S, Philpott DJ, Hu J.Activation of P2X(7) receptor by ATP plays an important role in regulating inflammatory responses during acute viral infection. PLoS One 2012; 7: e35812.
168. Crofford LJ. COX-1 and COX-2 tissue expression: implicationsand predictions. J Rheumatol Suppl 1997; 49: 15-9.
169. Ashton AW, Mukherjee S, Nagajyothi FN, et al. Thromboxane A2is a key regulator of pathogenesis during Trypanosoma cruzi infection. J Exp Med 2007; 204: 929-40.
170. Culver CA, Laster SM. Adenovirus type 5 exerts multiple effectson the expression and activity of cytosolic phospholipase A2, cyclooxygenase-2, and prostaglandin synthesis. J Immunol 2007; 179: 4170-9.
171. Voskuhl R. Sex differences in autoimmune diseases. Biol SexDiffer 2011; 2: 1.
172. Dana R, Leto TL, Malech HL, Levy R. Essential requirement ofcytosolic phospholipase A2 for activation of the phagocyte NADPH oxidase. J Biol Chem 1998; 273: 441-5.
173. Deng X, Dong Y, Yi Q, et al. The determinants for the enzymeactivity of human parvovirus B19 phospholipase A2 (PLA2) and its influence on cultured cells. PLoS One 2013; 8: e61440.
174. Zádori Z, Szelei J, Lacoste MC, et al. A viral phospholipase A2 isrequired for parvovirus infectivity. Dev Cell 2001; 1: 291-302.
175. Marnett LJ, Rowlinson SW, Goodwin DC, Kalgutkar AS, Lanzo CA. Arachidonic acid oxygenation by COX-1 and COX-2. Mechanisms of catalysis and inhibition. J Biol Chem 1999; 274: 22903-6.
176. Salvemini D, Settle SL, Masferrer JL, Seibert K, Currie MG, Needleman P. Regulation of prostaglandin production by nitric oxide; an in vivo analysis. Br J Pharmacol 1995; 114: 1171-8.
177. Zou MH, Klein T, Pasquet JP, Ullrich V. Interleukin 1betadecreases prostacyclin synthase activity in rat mesangial cells viaendogenous peroxynitrite formation. Biochem J 1998; 336 (Pt 2): 507-12.
178. Uchida K. A lipid-derived endogenous inducer of COX-2: a bridgebetween inflammation and oxidative stress. Mol Cells 2008; 25: 347-51.
179. Reddy ST, Wadleigh DJ, Herschman HR. Transcriptionalregulation of the cyclooxygenase-2 gene in activated mast cells. J Biol Chem 2000; 275: 3107-13.
180. Hwang D, Jang BC, Yu G, Boudreau M. Expression of mitogen-inducible cyclooxygenase induced by lipopolysaccharide: mediation through both mitogen-activated protein kinase and NF- kappaB signaling pathways in macrophages. Biochem Pharmacol 1997; 54: 87-96.
181. Korbecki J, Baranowska-Bosiacka I, Gutowska I, Chlubek D. Theeffect of reactive oxygen species on the synthesis of prostanoids from arachidonic acid. J Physiol Pharmacol 2013; 64: 409-21.
182. Chi PL, Chen YW, Hsiao LD, Chen YL, Yang CM. Hemeoxygenase 1 attenuates interleukin-1 -induced cytosolic phospholipase A2 expression via a decrease in NADPH oxidase/reactive oxygen species/activator protein 1 activation in rheumatoid arthritis synovial fibroblasts. Arthritis Rheum 2012; 64: 2114-25.
183. Zhao G, Yu R, Deng J, et al. Pivotal role of reactive oxygenspecies in differential regulation of lipopolysaccharide-induced prostaglandins production in macrophages. Mol Pharmacol 2013; 83: 167-78.
184. Mathy-Hartert M, Martin G, Devel P, et al. Reactive oxygenspecies downregulate the expression of pro-inflammatory genes by human chondrocytes. Inflamm Res 2003; 52: 111-8.
185. Li Q, Harraz MM, Zhou W, et al. Nox2 and Rac1 regulate H2O2-dependent recruitment of TRAF6 to endosomal interleukin-1 receptor complexes. Mol Cell Biol 2006; 26: 140-54.
186. Moe KT, Yin NO, Naylynn TM, et al. Nox2 and Nox4 mediatetumour necrosis factor- -induced ventricular remodelling in mice. J Cell Mol Med 2011; 15: 2601-13.
187. Grieve DJ, Byrne JA, Siva A, et al. Involvement of thenicotinamide adenosine dinucleotide phosphate oxidase isoform Nox2 in cardiac contractile dysfunction occurring in response to pressure overload. J Am Coll Cardiol 2006; 47: 817-26.
188. Arumugam S, Thandavarayan RA, Veeraveedu PT, et al.Beneficial effects of edaravone, a novel antioxidant, in rats with dilated cardiomyopathy. J Cell Mol Med 2012; 16: 2176-85.
189. Brunori M, Forte E, Arese M, Mastronicola D, Giuffrè A, Sarti P.Nitric oxide and the respiratory enzyme. Biochim Biophys Acta 2006; 1757: 1144-54.
190. Horinaka S, Kobayashi N, Mori Y, Yagi H, Onoda M, Matsuoka H.Expression of inducible nitric oxide synthase, left ventricular function and remodeling in Dahl salt-sensitive hypertensive rats. Int J Cardiol 2003; 91: 25-35.
191. Zhang P, Xu X, Hu X, van Deel ED, Zhu G, Chen Y. Induciblenitric oxide synthase deficiency protects the heart from systolic overload-induced ventricular hypertrophy and congestive heart failure. Circ Res 2007; 100: 1089-98.
192. Cole MP, Chaiswing L, Oberley TD, et al. The protective roles ofnitric oxide and superoxide dismutase in adriamycin-induced cardiotoxicity. Cardiovasc Res 2006; 69: 186-97.
193. Zingarelli B, Hake PW, Yang Z, O'Connor M, Denenberg A, Wong HR. Absence of inducible nitric oxide synthase modulates early reperfusion-induced NF-kappaB and AP-1 activation and enhances myocardial damage. FASEB J 2002; 16: 327-42.
194. Nishida M, Ogushi M, Suda R, et al. Heterologous down-regulation of angiotensin type 1 receptors by purinergic P2Y2 receptor stimulation through S-nitrosylation of NF-kappaB. Proc Natl Acad Sci USA 2011; 108: 6662-7.
195. Mannick JB, Hausladen A, Liu L, et al. Fas-induced caspasedenitrosylation. Science 1999; 284: 651-4.
196. Numajiri N, Takasawa K, Nishiya T, et al. On-off system for PI3-kinase-Akt signaling through S-nitrosylation of phosphatase with sequence homology to tensin (PTEN). Proc Natl Acad Sci USA 2011; 108: 10349-54.
197. Hortelano S, Alvarez AM, Boscá L. Nitric oxide induces tyrosinenitration and release of cytochrome c preceding an increase of mitochondrial transmembrane potential in macrophages. FASEB J 1999; 13: 2311-7.
198. Cho DH, Nakamura T, Fang J, et al. S-nitrosylation of Drp1mediates beta-amyloid-related mitochondrial fission and neuronal injury. Science 2009; 324: 102-5.
199. Sawa T, Ihara H, Ida T, Fujii S, Nishida M, Akaike T. Formation,signaling functions, and metabolisms of nitrated cyclic nucleotide. Nitric Oxide 2013; 34: 10-8.
200. Nishida M, Sawa T, Kitajima N, et al. Hydrogen sulfide anionregulates redox signaling via electrophile sulfhydration. Nat Chem Biol 2012; 8: 714-24.
201. Hazan-Halevy I, Levy T, Wolak T, Lubarsky I, Levy R, Paran E.Stimulation of NADPH oxidase by angiotensin II in human neutrophils is mediated by ERK, p38 MAP-kinase and cytosolic phospholipase A2. J Hypertens 2005; 23: 1183-90.
202. Hu ZW, Kerb R, Shi XY, Wei-Lavery T, Hoffman BB.Angiotensin II increases expression of cyclooxygenase-2: implications for the function of vascular smooth muscle cells. J Pharmacol Exp Ther 2002; 303: 563-73.
203. Matsuno K, Yamada H, Iwata K, et al. Nox1 is involved inangiotensin II-mediated hypertension: a study in Nox1-deficient mice. Circulation 2005; 112: 2677-85.
204. Ushio-Fukai M. Localizing NADPH oxidase-derived ROS. SciSTKE 2006; 2006: re8.
205. Ferreira AJ, Shenoy V, Qi Y, et al. Angiotensin-converting enzyme2 activation protects against hypertension-induced cardiac fibrosis involving extracellular signal-regulated kinases. Exp Physiol 2011; 96: 287-94.
206. Zhong J, Basu R, Guo D, et al. Angiotensin-converting enzyme 2suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction. Circulation 2010; 122: 717-28, 18 p following 728.
207. Inaba S, Iwai M, Furuno M, et al. Role of angiotensin-convertingenzyme 2 in cardiac hypertrophy induced by nitric oxide synthase inhibition. J Hypertens 2011; 29: 2236-45.
208. Qi Y, Shenoy V, Wong F, et al. Lentivirus-mediatedoverexpression of angiotensin-(1-7) attenuated ischaemia-induced cardiac pathophysiology. Exp Physiol 2011; 96: 863-74.
209. Benter IF, Yousif MH, Dhaunsi GS, Kaur J, Chappell MC, Diz DI.Angiotensin-(1-7) prevents activation of NADPH oxidase and renal vascular dysfunction in diabetic hypertensive rats. Am J Nephrol 2008; 28: 25-33.
210. Patel VB, Bodiga S, Fan D, et al. Cardioprotective effects mediatedby angiotensin II type 1 receptor blockade and enhancing angiotensin 1-7 in experimental heart failure in angiotensin- converting enzyme 2-null mice. Hypertension 2012; 59: 1195-203.
211. McKinney CA, Fattah C, Loughrey CM, Milligan G, Nicklin SA.Angiotensin-(1-7) and angiotensin-(1-9): function in cardiac and vascular remodelling. Clin Sci (Lond) 2014; 126: 815-27.
212. Kayashima Y, Smithies O, Kakoki M. The kallikrein-kinin systemand oxidative stress. Curr Opin Nephrol Hypertens 2012; 21: 92-6.
213. Oeseburg H, Iusuf D, van der Harst P, van Gilst WH, Henning RH,Roks AJ. Bradykinin protects against oxidative stress-induced endothelial cell senescence. Hypertension 2009; 53: 417-22.
214. Kakoki M, McGarrah RW, Kim HS, Smithies O. Bradykinin B1and B2 receptors both have protective roles in renal ischemia/reperfusion injury. Proc Natl Acad Sci USA 2007; 104: 7576-81.
215. Kuhr F, Lowry J, Zhang Y, Brovkovych V, Skidgel RA.Differential regulation of inducible and endothelial nitric oxide synthase by kinin B1 and B2 receptors. Neuropeptides 2010; 44: 145-54.
216. Böckmann S, Paegelow I. Kinins and kinin receptors: importancefor the activation of leukocytes. J Leukoc Biol 2000; 68: 587-92.
217. Schulze-Topphoff U, Prat A, Prozorovski T, et al. Activation ofkinin receptor B1 limits encephalitogenic T lymphocyte recruitment to the central nervous system. Nat Med 2009; 15: 788-93.
218. Dutra RC, Leite DF, Bento AF, et al. The role of kinin receptors inpreventing neuroinflammation and its clinical severity during experimental autoimmune encephalomyelitis in mice. PLoS One 2011; 6: e27875.
219. Taylor EB, Rutter J. Mitochondrial quality control by the ubiquitin-proteasome system. Biochem Soc Trans 2011; 39: 1509-13.
220. Jahngen-Hodge J, Obin MS, Gong X, et al. Regulation ofubiquitin-conjugating enzymes by glutathione following oxidative stress. J Biol Chem 1997; 272: 28218-26.
221. Seifert U, Bialy LP, Ebstein F, et al. Immunoproteasomes preserveprotein homeostasis upon interferon-induced oxidative stress. Cell 2010; 142: 613-24.
222. Si X, Gao G, Wong J, Wang Y, Zhang J, Luo H. Ubiquitination isrequired for effective replication of coxsackievirus B3. PLoS One 2008; 3: e2585.
223. Luo H, Zhang J, Cheung C, Suarez A, McManus BM, Yang D.Proteasome inhibition reduces coxsackievirus B3 replication in murine cardiomyocytes. Am J Pathol 2003; 163: 381-5.
224. Luo H, Zhang J, Dastvan F, et al. Ubiquitin-dependent proteolysisof cyclin D1 is associated with coxsackievirus-induced cell growth arrest. J Virol 2003; 77: 1-9.
225. Rivett AJ, Hearn AR. Proteasome function in antigen presentation:immunoproteasome complexes, Peptide production, and interactions with viral proteins. Curr Protein Pept Sci 2004; 5: 153-61.
226. Gao G, Zhang J, Si X, Wong J, Cheung C, McManus B, Luo H.Proteasome inhibition attenuates coxsackievirus-induced myocardial damage in mice. Am J Physiol Heart Circ Physiol 2008; 295: H401-8.
227. Wang Y, Sun W, Du B, et al. Therapeutic effect of MG-132 ondiabetic cardiomyopathy is associated with its suppression of proteasomal activities: roles of Nrf2 and NF- B. Am J Physiol Heart Circ Physiol 2013; 304: H567-78.
228. Si X, McManus BM, Zhang J, et al. Pyrrolidine dithiocarbamatereduces coxsackievirus B3 replication through inhibition of the ubiquitin-proteasome pathway. J Virol 2005; 79: 8014-23.
229. Opitz E, Koch A, Klingel K, et al. Impairment ofimmunoproteasome function by 5i/LMP7 subunit deficiency results in severe enterovirus myocarditis. PLoS Pathog 2011; 7: e1002233.
230. Weekes J, Morrison K, Mullen A, Wait R, Barton P, Dunn MJ. Hyperubiquitination of proteins in dilated cardiomyopathy. Proteomics 2003; 3: 208-16.
231. Wen JJ, Yachelini PC, Sembaj A, Manzur RE, Garg NJ. Increasedoxidative stress is correlated with mitochondrial dysfunction in chagasic patients. Free Radic Biol Med 2006; 41: 270-6.
232. Hiraoka Y, Kishimoto C, Kurokawa M, Ochiai H, Sasayama S.Effects of polyethylene glycol conjugated superoxide dismutase on coxsackievirus B3 myocarditis in mice. Cardiovasc Res 1992; 26: 956-61.
233. Rosenbaugh EG, Savalia KK, Manickam DS, Zimmerman MC.Antioxidant-based therapies for angiotensin II-associated cardiovascular diseases. Am J Physiol Regul Integr Comp Physiol 2013; 304: R917-28.
234. Shimada K, Uzui H, Ueda T, Lee JD, Kishimoto C. N-acetylcysteine ameliorates experimental autoimmune myocarditis in rats via nitric oxide. J Cardiovasc Pharmacol Ther 2015; 20: 203-10.
235. Rowbotham DS, Wendon JA, Harrison PM. N-acetylcysteineinfusion in viral myocarditis: a case report. Int J Cardiol 1997; 60: 315-6.
236. Keum YS. Regulation of the Keap1/Nrf2 system bychemopreventive sulforaphane: implications of posttranslational modifications. Ann N Y Acad Sci 2011; 1229: 184-9.
237. Wu CC, Chuang HY, Lin CY, et al. Inhibition of Epstein-Barrvirus reactivation in nasopharyngeal carcinoma cells by dietary sulforaphane. Mol Carcinog 2013; 52: 946-58.
238. Kesic MJ, Simmons SO, Bauer R, Jaspers I. Nrf2 expressionmodifies influenza A entry and replication in nasal epithelial cells. Free Radic Biol Med 2011; 51: 444-53.
239. Schachtele SJ, Hu S, Lokensgard JR. Modulation of experimentalherpes encephalitis-associated neurotoxicity through sulforaphane treatment. PLoS One 2012; 7: e36216.
240. Grootveld M, Halliwell B, Moorhouse CP. Action of uric acid,allopurinol and oxypurinol on the myeloperoxidase-derived oxidant hypochlorous acid. Free Radic Res Commun 1987; 4: 69-76.
241. Moorhouse PC, Grootveld M, Halliwell B, Quinlan JG, Gutteridge JM. Allopurinol and oxypurinol are hydroxyl radical scavengers. FEBS Lett 1987; 213: 23-8.
242. Oláh T, Régely K, Mándi Y. The inhibitory effects of allopurinolon the production and cytotoxicity of tumor necrosis factor. Naunyn Schmiedebergs Arch Pharmacol 1994; 350: 96-9.
243. Pérez-Mazliah D, Albareda MC, Alvarez MG, et al. Allopurinolreduces antigen-specific and polyclonal activation of human T cells. Front Immunol 2012; 3: 295.
244. Kato C, Sato K, Wakabayashi A, Eishi Y. The effects ofallopurinol on immune function in normal BALB/c and SCID mice. Int J Immunopharmacol 2000; 22: 547-56.
245. Augustin AJ, Loeffler KU, Sekundo W, Grus FH, Lutz J. Effects ofsystemically applied allopurinol and prednisolone on experimental autoimmune uveitis. Graefes Arch Clin Exp Ophthalmol 1999; 237: 508-12.
246. Schwartz MD, Repine JE, Abraham E. Xanthine oxidase-derivedoxygen radicals increase lung cytokine expression in mice subjected to hemorrhagic shock. Am J Respir Cell Mol Biol 1995; 12: 434-40.
247. Suzuki J, Ogawa M, Futamatsu H, Kosuge H, Tanaka H, Isobe M.A cyclooxygenase-2 inhibitor alters Th1/Th2 cytokine balance and suppresses autoimmune myocarditis in rats. J Mol Cell Cardiol 2006; 40: 688-95.
248. Takayama K, García-Cardena G, Sukhova GK, Comander J,Gimbrone MA, Libby P. Prostaglandin E2 suppresses chemokine production in human macrophages through the EP4 receptor. J Biol Chem 2002; 277: 44147-54.
249. Ngoc PB, Suzuki J, Ogawa M, et al. The anti-inflammatorymechanism of prostaglandin e2 receptor 4 activation in rat experimental autoimmune myocarditis. J Cardiovasc Pharmacol 2011; 57: 365-72.
250. Gruhle S, Sauter M, Szalay G, Ettischer N, Kandolf R, Klingel K.The prostacyclin agonist iloprost aggravates fibrosis and enhances viral replication in enteroviral myocarditis by modulation of ERK signaling and increase of iNOS expression. Basic Res Cardiol 2012; 107: 287.
251. Takahashi T, Zhu SJ, Sumino H, et al. Inhibition ofcyclooxygenase-2 enhances myocardial damage in a mouse model of viral myocarditis. Life Sci 2005; 78: 195-204.
252. Cheng Y, Austin SC, Rocca B, et al. Role of prostacyclin in thecardiovascular response to thromboxane A2. Science 2002; 296: 539-41.
253. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular eventsassociated with selective COX-2 inhibitors. JAMA 2001; 286: 954-9.
254. Chenevard R, Hürlimann D, Béchir M, et al. Selective COX-2inhibition improves endothelial function in coronary artery disease. Circulation 2003; 107: 405-9.
255. Mortensen SA, Rosenfeldt F, Kumar A, et al. The effect ofcoenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial. JACC Heart Fail 2014; 2: 641-9.
256. Kishimoto C, Tomioka N, Nakayama Y, Miyamoto M. Anti-oxidant effects of coenzyme Q10 on experimental viral myocarditis in mice. J Cardiovasc Pharmacol 2003; 42: 588-92.
257. Wen JJ, Bhatia V, Popov VL, Garg NJ. Phenyl-alpha-tert-butylnitrone reverses mitochondrial decay in acute Chagas' disease. Am J Pathol 2006; 169: 1953-64.
258. Shimazaki H, Watanabe K, Veeraveedu PT, et al. The antioxidantedaravone attenuates ER-stress-mediated cardiac apoptosis and dysfunction in rats with autoimmune myocarditis. Free Radic Res 2010; 44: 1082-90.
259. Arumugam S, Thandavarayan RA, Veeraveedu PT, et al.Involvement of AMPK and MAPK signaling during the progression of experimental autoimmune myocarditis in rats and its blockade using a novel antioxidant. Exp Mol Pathol 2012; 93: 183-9.
260. Tanaka A, Matsumori A, Wang W, Sasayama S. An angiotensin IIreceptor antagonist reduces myocardial damage in an animal model of myocarditis. Circulation 1994; 90: 2051-5.
261. Yamamoto K, Shioi T, Uchiyama K, Miyamoto T, Sasayama S, Matsumori A. Attenuation of virus-induced myocardial injury by inhibition of the angiotensin II type 1 receptor signal and decreased nuclear factor-kappa B activation n in knockout mice. J Am Coll Cardiol 2003; 42: 2000-6.
262. Seko Y. Effect of the angiotensin II receptor blocker olmesartan onthe development of murine acute myocarditis caused by coxsackievirus B3. Clin Sci (Lond) 2006; 110: 379-86.
263. Xiao J, Shimada M, Liu W, Hu D, Matsumori A. Anti-inflammatory effects of eplerenone on viral myocarditis. Eur J Heart Fail 2009; 11: 349-53.
264. Sukumaran V, Watanabe K, Veeraveedu PT, et al. Telmisartanameliorates experimental autoimmune myocarditis associated withinhibition of inflammation and oxidative stress. Eur J Pharmacol 2011; 652: 126-35.
265. Sukumaran V, Veeraveedu PT, Gurusamy N, et al. Olmesartanattenuates the development of heart failure after experimental autoimmune myocarditis in rats through the modulation of ANG 1-7 mas receptor. Mol Cell Endocrinol 2012; 351: 208-19.
266. Ferrario CM, Jessup J, Chappell MC, et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation 2005; 111: 2605-10.
267. Messadi E, Vincent MP, Griol-Charhbili V, et al. Geneticallydetermined angiotensin converting enzyme level and myocardial tolerance to ischemia. FASEB J 2010; 24: 4691-700.
268. Manolis AJ, Marketou ME, Gavras I, Gavras H. Cardioprotectiveproperties of bradykinin: role of the B(2) receptor. Hypertens Res 2010; 33: 772-7.
269. Erdös EG, Tan F, Skidgel RA. Angiotensin I-converting enzymeinhibitors are allosteric enhancers of kinin B1 and B2 receptor function. Hypertension 2010; 55: 214-20.
270. Bahk TJ, Daniels MD, Leon JS, Wang K, Engman DM.Comparison of angiotensin converting enzyme inhibition and angiotensin II receptor blockade for the prevention of experimental autoimmune myocarditis. Int J Cardiol 2008; 125: 85-93.
271. Liaudet L, Calderari B, Pacher P. Pathophysiological mechanismsof catecholamine and cocaine-mediated cardiotoxicity. Heart Fail Rev 2014; 19: 815-24.
272. Bindoli A, Deeble DJ, Rigobello MP, Galzigna L. Direct andrespiratory chain-mediated redox cycling of adrenochrome. Biochim Biophys Acta 1990; 1016: 349-56.
273. Hieda Y, Anraku M, Choshi T, et al. Antioxidant effects of thehighly-substituted carbazole alkaloids and their related carbazoles. Bioorg Med Chem Lett 2014; 24: 3530-3.
274. Bowman AJ, Chen CP, Ford GA. Nitric oxide mediated venodilatoreffects of nebivolol. Br J Clin Pharmacol 1994; 38: 199-204.
275. Afonso RA, Patarrao RS, Macedo MP, Carmo MM. Carvedilolaction is dependent on endogenous production of nitric oxide. Am J Hypertens 2006; 19: 419-25.
276. Khan MU, Zhao W, Zhao T, et al. Nebivolol: a multifacetedantioxidant and cardioprotectant in hypertensive heart disease. J Cardiovasc Pharmacol 2013; 62: 445-51.
277. Yuan Z, Shioji K, Kihara Y, Takenaka H, Onozawa Y, KishimotoC. Cardioprotective effects of carvedilol on acute autoimmune myocarditis: anti-inflammatory effects associated with antioxidant property. Am J Physiol Heart Circ Physiol 2004; 286: H83-H90.
278. Yue-Chun L, Li-Sha G, Jiang-Hua R, et al. Protective effects ofcarvedilol in murine model with the coxsackievirus B3-induced viral myocarditis. J Cardiovasc Pharmacol 2008; 51: 92-8.
279. Wang JF, Meissner A, Malek S, et al. Propranolol ameliorates andepinephrine exacerbates progression of acute and chronic viral myocarditis. Am J Physiol Heart Circ Physiol 2005; 289: H1577-H1583.
280. Tominaga M, Matsumori A, Okada I, Yamada T, Kawai C. Beta-blocker treatment of dilated cardiomyopathy. Beneficial effect of carteolol in mice. Circulation 1991; 83: 2021-8.
281. Glück B, Dahlke K, Zell R, et al. Cardioprotective effect of NO-metoprolol in murine coxsackievirus B3-induced myocarditis. J Med Virol 2010; 82: 2043-52.
282. Suzuki J, Ogawa M, Futamatsu H, Kosuge H, Sagesaka YM, Isobe M. Tea catechins improve left ventricular dysfunction, suppress myocardial inflammation and fibrosis, and alter cytokine expression in rat autoimmune myocarditis. Eur J Heart Fail 2007; 9: 152-9.
283. Frei B, Higdon JV. Antioxidant activity of tea polyphenols in vivo:evidence from animal studies. J Nutr 2003; 133: 3275S-3284S.
284. Nakagawa H, Hasumi K, Woo JT, Nagai K, Wachi M. Generationof hydrogen peroxide primarily contributes to the induction of Fe(II)-dependent apoptosis in Jurkat cells by (-)-epigallocatechin gallate. Carcinogenesis 2004; 25: 1567-74.
285. Khan N, Afaq F, Saleem M, Ahmad N, Mukhtar H. Targetingmultiple signaling pathways by green tea polyphenol (-)- epigallocatechin-3-gallate. Cancer Res 2006; 66: 2500-5.
286. Stangl V, Dreger H, Stangl K, Lorenz M. Molecular targets of teapolyphenols in the cardiovascular system. Cardiovasc Res 2007; 73: 348-58.
287. Arumugam S, Mito S, Thandavarayan RA, et al. Mulberry leaf dietprotects against progression of experimental autoimmunemyocarditis to dilated cardiomyopathy via modulation of oxidative stress and MAPK-mediated apoptosis. Cardiovasc Ther 2013; 31: 352-62.
288. Song Y, Ge W, Cai H, Zhang H. Curcumin protects mice from coxsackievirus B3-induced myocarditis by inhibiting thephosphatidylinositol 3 kinase/Akt/nuclear factor- B pathway. J Cardiovasc Pharmacol Ther 2013; 18: 560-9.
289. Izem-Meziane M, Djerdjouri B, Rimbaud S, et al. Catecholamine- induced cardiac mitochondrial dysfunction and mPTP opening:protective effect of curcumin. Am J Physiol Heart Circ Physiol 2012; 302: H665-74.
290. Factor SM, Cho SH, Scheuer J, Sonnenblick EH, Malhotra A. Prevention of hereditary cardiomyopathy in the Syrian hamsterwith chronic verapamil therapy. J Am Coll Cardiol 1988; 12: 1599-604.
291. Sonnenblick EH, Fein F, Capasso JM, Factor SM. Microvascular spasm as a cause of cardiomyopathies and the calcium-blockingagent verapamil as potential primary therapy. Am J Cardiol 1985; 55: 179B-184B.